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Abstract
Background: Post-treatment contralateral hemiliver hypertrophy has created an interest in lobar liver
radioembolization (RE) as a pre-surgery tool.
Methods: Liver and spleen volumes and function were studied in 83 patients submitted to partial liver
volume RE at 4–8 weeks (T1), 10–26 weeks (T2), and >26 weeks (T3) after RE.
Results: More than half of the patients had cirrhosis with hepatocellular carcinoma. The main finding
was a progressive increase in the volume of the spared hemiliver (mean absolute increase at T3: 230 ml).
The percentage of patients in whom the baseline ratio of spared volume to total liver volume was <40%
dropped from 56.6% at baseline to 29.4% at T2 (P < 0.001). A significant and progressive increase in
spleen volume but not in portal vein diameter was also observed. A small percentage of patients
developed hypersplenism, mostly those without cirrhosis (16.0% at T2). Six patients (five with portal vein
thrombosis, cirrhosis or both) developed signs of portal hypertension by T2.
Conclusions: The present results warrant further studies to better elucidate the mechanism underlying
this phenomenon of spared hemiliver hypertrophy and to investigate its role as an alternative to portal vein
embolization in the management of patients with potentially resectable liver tumours.
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Introduction
According to the last report of the International Agency for
Research on Cancer, primary liver cancer is the sixth most
common malignancy worldwide and the third most common
cause of cancer-related mortality.1 The liver is also one of the
organs most frequently affected by metastases from distant
primary tumours. Curative treatment for liver tumours may
consist of liver transplant, resection or percutaneous ablation.
However, in many patients surgical treatment is contraindicated
by inappropriate liver function, an extrahepatic tumour burden or
the lack of a sufficient future liver remnant (FLR).When an exces-
sive extent of disease precludes liver resection, downstaging strat-
egies play an important role in rescuing patients for surgery.2
Similarly, when the FLR is expected to be insufficient, portal vein
embolization (PVE) is used in preoperative management to
induce selective hepatic hypertrophy.3
Liver radioembolization (RE) has been developed in recent
years. It consists of the intra-arterial delivery of microspheres
loaded with yttrium-90. Diverse evidence supports its use in dif-
ferent types of hepatic tumour, including both primary and meta-
static disease, as well as hepatocellular carcinoma4 and liver
metastases from colorectal cancer5 and neuroendocrine tumours.6
Although RE is commonly used as a palliative treatment, it has
also been performed in some instances to downstage patients to
salvage surgery, and to avoid progression until surgery (i.e. as
treatment administered to a patient on the waiting list for resec-
tion or liver transplantation).7–10 Some authors have reported the
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occurrence of hypertrophy in the spared hemiliver after lobar,
segmental or sequential lobar RE,11–14 raising the question of
whether it could be deliberately used for this purpose in a manner
similar to that of PVE. In this setting, the potential deleterious
effects on the non-tumoral liver, including the development of
portal hypertension and RE-induced liver disease, may pose tech-
nical difficulties in liver surgery.15 The purpose of this study was to
analyse changes in liver and spleen volumes and function in
patients treated with RE when only a partial volume is targeted.
Materials and methods
Patient cohort
The study population included all patients submitted to RE at the
study institution between September 2003 and September 2010 in
whom: (i) lobar or segmental treatment was performed, with or
without flow redistribution; (ii) all image examinations [angiog-
raphy, nuclear medicine scans, computed tomography (CT) and
magnetic resonance imaging (MRI)] were performed in the same
institution; (iii) screening angiography was performed no more
than 15 days before treatment, and (iv) follow-up cross-sectional
imaging studies were performed in weeks 4–8 (T1), weeks 10–26
(T2), and at >26 weeks (T3) after RE. In patients who received a
second RE treatment to the treated or spared hemiliver or who
were submitted to a major hepatic intervention after RE (hepate-
ctomy, biliary drainage, trans jugular intrahepatic portosystemic
stent shunt), those images obtained following this second event
were excluded from analysis. The term ‘spared hemiliver’ will be
used hereafter to distinguish the untreated hemiliver from the
treated hemiliver (the entire hemiliver or one or more segments).
General inclusion criteria for RE at this institution include an
unequivocal diagnosis of unresectable primary or metastatic
cancer with a liver-only or liver-dominant tumour burden, a life
expectancy of >3 months and an Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2, adequate pulmonary,
haematology, hepatic and renal function, and the possibility to
deliver to the lungs an estimated dose of radiation of < 30 Gy.
Approval for this retrospective analysis was obtained from the
local ethics committee.
Pretreatment and treatment
Pretreatment investigations included cross-sectional imaging
studies with CT or MRI, blood cell count and serum bio-
chemistry. All previous images were carefully evaluated before
angiographic mapping of the abdominal visceral and hepatic
arteries was carried out. The techniques for the isolation of the
hepatic vasculature and vascular redistribution have been well
described16,17 and were followed in pre-treatment angiographic
planning. Calculation of the lung-shunting fraction, pretreat-
ment identification of infusion patterns, detection of any non-
target infused liver volume and the unintentional delivery of
radioactive particles to organs outside the liver were also evalu-
ated after the infusion of technetium-99 m-labelled macroaggre-
gated albumin (99mTc-MAA).
The treatment to be prescribed was calculated according to the
body surface area formula or the compartmental model and
injected within 15 days of the 99mTc-MAA scan. On the day of
treatment, a new angiographic study was performed to exclude
any changes in the vascular anatomy of the target volume and,
in accordance with current recommendations, the delivery of
yttrium-90-labeled resin microspheres (SIR-Spheres; Sirtex
Medical Ltd, Sydney, NSW, Australia) was accomplished with a
coaxially inserted microcatheter through one or two major affer-
ent tumoral arteries, at the same injection site as the initial evalu-
ation with 99mTc-MAA.
Follow-up and statistical analysis
All CT and MRI images were analysed by two radiologists with,
respectively, 3 years and 5 years of experience on a Leonardo
Workstation (Siemens AGMedical Solutions, Erlangen, Germany)
and volumes were determined using 1-cm-thick reformatted
images with standard Syngo software tools. The volumes of the
right and left livers and the spleen were measured, as was the
maximal diameter of the main portal vein before bifurcation.
Total liver volume was calculated as the sum of the volumes of the
right and left livers. All images were searched for the presence of
portal vein thrombosis and indirect signs of portal hypertension
including re-permeabilization of the umbilical vein, splenorenal
shunt and gastro-oesophageal varices. Blood cell counts and liver
function tests (serum transaminases, total bilirubin, albumin, pro-
thrombin time) obtained at the time of cross-sectional imaging
studies were used to evaluate changes in liver and spleen function.
Changes in the volumes of the treated and spared hemilivers,
spleen volume, diameter of the main portal vein, platelet count,
blood cell count and liver function tests between baseline and the
three time intervals post-RE were studied using Student’s t-test for
paired samples. The association between changes in spared liver
volume and baseline variables was studied using Student’s t-test
for unpaired samples. The correlation between the volume of the
spared hemiliver before treatment and baseline total bilirubin
levels and their change after RE were studied using analysis of
variance (anova). All statistical analyses were performed using
spss Version 10.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patients
A total of 83 patients submitted to RE between September 2003
and September 2010, in whom at least a single hemiliver was
preserved from radiation, were found to fulfil all of the patient
selection criteria. Their general characteristics are summarized in
Table 1.Most patients had primary liver tumours (67.5%), usually
with underlying cirrhosis (53.0%). Liver and haematological
functions were basically preserved. Only 16.0% of patients were
found to have hypersplenism as defined by a platelet count of
<100·10e9/l. The right liver was targeted in 80.0% of patients. In
10.8% of patients, the target area involved one or more segments
but not the entire right or left liver (segmental treatment). A total
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of 29 patients (34.9%) had been exposed to chemotherapy prior
to RE, including 18 patients with liver metastases from colorectal
or breast cancer who had received several lines of therapy. A total
of 54 patients (65.1%) were chemo-naïve at the time of RE; these
included 49 patients with hepatocellular carcinoma, three patients
with cholangiocarcinoma, and two patients with liver metastases
from neuroendocrine tumours who had received only somatosta-
tin analogues and/or interferon.
Changes in liver volume and function
The main finding was a progressive and statistically significant
increase in the volume of the spared hemiliver, which was already
significant at T1, but continued to rise until maximal follow-up
(Fig. 1). The mean  standard deviation (SD) absolute increase
was 73.1  137.7 ml at T1, 134.7  193.9 ml at T2, and 229.7 
303.0 ml at T3 (P < 0.001 for each time period). This was paral-
leled by a statistically significant decrease in the volume of the
treated hemiliver, although the magnitude of this change was not
as large as for the spared hemiliver. The mean  SD absolute
decrease was 64.5  198.3 ml at T1, 218.6  287.4 ml at T2, and
321.9  375.6 ml at T3 (P < 0.001 for each period). These results
remained significant when patients with progression of existing
tumours or development of new tumours in the spared hemiliver
were excluded from analysis. In addition, the results remained
consistent irrespective of whether the left or right hemiliver was
treated.Globally, themean SD total liver volume did not change
significantly from baseline (2008  801 ml) to T1 (2081 
972 ml; P = 0.841), T2 (1848 950 ml; P = 0.081) or T3 (1649
658 ml; P = 0.335) because the hypertrophy of the spared
hemiliver compensated for the atrophy of the treated hemiliver.
The ratio between the volume of the spared hemiliver and the
volume of the total liver was also calculated. In patients in whom
this ratio was found to be <40%, the mean  SD ratio rose from
29 6% at baseline to 32 8% at T1, 40 12% at T2 and 50
13% at T3 (P < 0.001 for each time interval). Even more impor-
tantly, the percentage of patients with a ratio of <40% declined
from 56.6% at baseline to 47.6% at T1 (P < 0.001), 29.4% at T2
(P < 0.001) and 15.6% at T3 (P = 0.155).
A clinically irrelevant but statistically significant increase in
mean  SD serum total bilirubin was observed from baseline
(0.92  0.86 mg/ml) to T1 (0.93  1.16 mg/ml; P = 0.015), T2
(1.13  1.57 mg/ml; P = 0.000) and T3 (1.59  1.22 mg/ml;
P < 0.001). However, no significant changes related to synthetic
liver function (prothrombin time and albumin) were seen.
Table 1 General characteristics of patients in the present series
treated with radioembolization
Patients, n 83
Age, years, median  IQR 66  13
Sex, male, n (%) 61 (73.5%)
Type of tumour, n (%)
• Hepatocellular carcinoma 52 (62.7%)
• Cholangiocarcinoma 4 (4.8%)
• Colorectal cancer 13 (15.7%)
• Other 14 (16.8%)
Prior chemotherapy, n (%) 29 (34.9%)
Cirrhosis, n (%) 44 (53.0%)
Portal vein thrombosis, n (%) 8 (9.6%)
Haemoglobin, g/dl, median  IQR 12.80  3.05
Leukocytes, 109/l, median  IQR 5.9  3.3
Platelets, 109/l, median  IQR 163  145
Albumin, g/dl, median  IQR 3.73  0.80
Prothrombin time, s, median  IQR 12.5  2.1
AST, UI/l, median  IQR 30.0  35.5
ALT, UI/l, median  IQR 23.0  32.5
Alkaline phosphatase, UI/l, median  IQR 168.5  140.0
g-GTP, UI/l, median  IQR 85.5  120.5
Total bilirubin, mg/dl, median  IQR 0.92  0.86
Treated volume, n (%)
• Right liver 60 (72.3%)
• Left liver 14 (16.9%)
• One or more right segments 6 (7.2%)
• One or more left segments 3 (3.6%)
Sites of microsphere infusion, n (%)
• Right liver artery 56 (67.4%)
• Left liver artery 11 (13.2%)
• Segmental arteries 13 (15.6%)
• Other 3 (3.6%)
g-GTP, g-glutamyl transpeptidase; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; IQR, inter-quartile range.
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Figure 1 Changes in the volume of the spared hemiliver following
partial liver volume radioembolization
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Different baseline conditions were analysed in an attempt to
identify factors that might determine the magnitude of the spared
hemiliver hypertrophy (Fig. 2). The degree of hypertrophy was
not significantly associated with sex, prior chemotherapy or an
abnormal platelet count, transaminase level or prothrombin time
at baseline. However, there was a trend to reduced hypertrophy
among patients with cirrhosis or an abnormal baseline total
bilirubin (>1.2 mg/dl), although the difference did not reach sta-
tistical significance (P = 0.08). No correlation between the esti-
mated dose of radiation delivered to the treated hemiliver
(calculated using the partition model) and changes in volume at
T1, T2 and T3 were seen.
Finally, there was no significant correlation between the degree
of hypertrophy of the spared hemiliver at any time-point and the
volumes of the spared and ipsilateral hemi livers before RE.
However, a correlation emerged between baseline total bilirubin
level and the degree of hypertrophy of the spared hemiliver
(Fig. 3).
Changes in spleen volume and function, and signs of
portal hypertension
As shown in Fig. 4, a significant and progressive increase in mean
 SD spleen volume was observed from baseline (447  283 ml)
to T1 (484 349 ml; P = 0.009), T2 (497 303 ml; P = 0.003) and
T3 (576  281 ml; P = 0.031). By contrast, platelet counts
remained basically stable over time, except at T2, when a mild but
statistically significant decrease in platelet count was observed.
However, the percentage of patients with hypersplenism was
16.0% at baseline, 17.5% at T1, 26.2% at T2, and 36.7% at T3.
Most of the patients who developed hypersplenism did not have
cirrhosis and thus the percentage of non-cirrhotic patients with
hypersplenism was 0% at baseline and 16.0% at T2. These changes
in spleen size and function did not differ between patients with
and without cirrhosis, or between those exposed and not exposed
to chemotherapy before RE.
The increase in spleen size was not accompanied by changes in
the diameter of the main portal vein. The mean SD diameter of
the main portal vein was 1.42  0.33 cm at baseline, 1.39 
0.33 cm (P = 0.474) at T1, 1.45  0.30 cm (P = 0.344) at T2, and
1.52 0.34 cm (P = 0.895) at T3. At baseline, 26 patients (31.3%)
had signs of portal hypertension. Six additional patients (7.2%)
developed such signs by T2 (indicated by the re-permeabilization
of the umbilical vein in four patients and the appearance of
varices in two). All but one of these six patients had other condi-
tions at baseline that might cause portal hypertension, including
portal vein thrombosis, cirrhosis or both, and portal vein tumour
invasion progressed after RE in two of these patients. The average
increase in spleen volume was 53.3% in these six patients and
9.9% in patients who did not develop signs of portal hypertension
(P = 0.127).
Discussion
Candidates for liver surgery with a supposedly insufficient FLR
can be treated with PVE to induce selective liver hypertrophy and
minimize the risk for liver insufficiency after surgery. The
methods and materials used for PVE are not fully standardized.18
The conventional approach is transparietohepatic and different
embolic materials have been used.19 Although the time needed to
achieve significant hypertrophy after PVE depends on the proce-
dure and material used, it does not usually take <4–5 weeks. In
recent years, new experimental embolization techniques and
materials have been developed in an attempt to obtain more
hypertrophy with fewer complications. These new techniques
have been explored only in animal models and include transarte-
rial embolization20 and transinusoidal PVE.21
Radioembolization has been used to downstage patients in
order to salvage them for surgery and to bridge patients for liver
transplantation.7–10 Some authors have recently reported hyper-
trophy of the spared hemiliver after RE when only a partial liver
volume is targeted. Jakobs et al. analysed volumetric liver and
spleen changes occurring 4–6 weeks after the treatment of the
right liver in 17 patients receiving sequential bilobar RE, and 30
days after treatment in 15 patients receiving lobar (right or left)
RE.12 Median hypertrophy in the spared hemiliver was 4% after
sequential RE, 9% after lobar RE and a significant 17% after right
lobar RE (in 10 patients). This concept was further explored in a
subsequent analysis by the same group in 20 patients treated with
right lobar RE. After an average of 18 months (range: 2–49
months), the authors observed atrophy of 52% in the treated
hemiliver, compensated by hypertrophy of 40% in the spared
hemiliver.14 These results are in agreement with the hypertrophy
of almost 45% achieved at >26 weeks after RE in the present
study.
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In general, most surgical teams would agree that the minimum
volume of the FLR required to allow safe resection is 20% in
patients with no underlying liver disease, 30% in patients who
have received chemotherapy prior to surgery, and 40% in patients
with chronic liver disease.22,23 In this regard, the finding in the
present series of a significant decline in the number of patients
with a ratio of spared hemi liver volume to total liver volume of
<40% at weeks 10–26 is remarkable. Tumour progression may
occur after PVE in both the embolized and the non-embolized
hemilivers. Whether this represents the natural history of the
tumour or whether PVE may foster this progression is not clear,24
although some studies have suggested that tumour growth in the
embolized hemiliver may be accelerated after PVE.25,26 On the
basis of this information, some authors have proposed the use of
anticancer chemotherapy after PVE27 or transarterial chemoem-
bolization (TACE) before PVE28,29 to control tumour growth, and
have obtained apparently good results in terms of hypertrophy,
complications and prognosis. Gulec et al.13 first reported on the
deliberate use of chemotherapy and RE to increase the FLR in a
patient with a history of treated cervical cancer and a voluminous
tumour mass in the right liver in which a right hepatectomy was
later safely performed. As observed in the present series, spared
hemiliver hypertrophy after RE is an early yet evolving phenom-
enon and the most clinically relevant changes usually occur after
10 weeks post-RE. This is a longer period than that usually
observed after PVE. In patients with liver metastases from color-
ectal cancer, this may necessitate the concomitant use of chemo-
therapy, whereas in patients with primary liver tumours, it may
allow for the natural selection of candidates without progression
in the untreated hemiliver. Given that PVE is associated with
adverse reactions in up to 15% of patients,19 partial volume RE
may represent an appealing alternative. Whether increasing the
dose of radiation to deliberately produce liver damage in the
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treated hemiliver may further enhance hypertrophy is not known.
The present results indicate that hypertrophy may occur when the
dose is only therapeutic.
By contrast, the reduced amount of radiation delivered to the
non-tumoral liver can cause tissue damage that occasionally
translates into clinical findings, such as altered liver function
tests, portal hypertension or subacute sinusoidal obstruction
syndrome.30–32 In agreement with previous series,12 the authors
observed a significant increase in spleen volume, but no increase
in portal vein diameter after lobar RE, as has been described after
whole-liver RE.11 However, only sporadically was this increase in
spleen volume associated with the development or aggravation of
hypersplenism, which raises the possibility that alternative causes
may explain such RE-induced splenomegaly. Interestingly,
patients without cirrhosis developed hypersplenism more fre-
quently than those with cirrhosis. Whether or not minor changes
in portal pressure may occur after RE, such changes rarely pose a
surgical problem. In fact, 15 of the present patients underwent
liver surgery (liver transplantation and major hepatectomy) after
RE without major complications.
The mechanism by which lobar RE induces contralateral liver
hypertrophy is not known. The consistent association with ipsi-
lateral atrophy strongly suggests that it may well be a compensa-
tory effect. Whole-liver RE can cause liver atrophy11,12,33 and
different types of histopathological liver damage have been
described in asymptomatic patients treated with RE, including
periportal fibrosis,13 portal ‘triaditis’34 and necrosis followed by
fibrosis and regenerative activity at the periphery of the tumour
where the level of radiation is maximal.35,36 The atrophy–
hypertrophy complex and the proliferating signalling pathways
involved in hepatocyte proliferation after PVE37,38 may also be
triggered after lobar RE as the radiation emitted by microspheres
embolized into the terminal hepatic arteries certainly may reach
the terminal portal venules. Importantly, this microscopic damage
rarely produces clinical problems in lobar RE. No significant
increases in liver transaminases or synthetic liver function tests
were seen in the present study, although a mild and clinically
irrelevant elevation in bilirubin was observed, as reported previ-
ously.14 Further prospective studies in animal models and patients
may help to elucidate these mechanisms.
Linked to its retrospective nature, the main weakness of this
study concerns the reduction in its sample size over the period of
study. However, this weakness is partly offset by the number of
patients (it is to date the largest series reporting on changes in liver
and spleen volumes) and the consistency of the main results (pro-
gressive hypertrophy of the spared hemiliver and increased spleen
size with minor hypersplenism) across analyses of different
subsets of patients.
In summary, the present study demonstrates that partial liver
volume RE induces significant hypertrophy in the spared
hemiliver and the magnitude of this increase tends to be lower in
patients with cirrhosis and an abnormal baseline bilirubin level.
Although spleen size increases after lobar RE, the lack of increase
in portal vein diameter and the only occasional development of
hypersplenism or radiological signs of portal hypertension
prevent the conclusion that lobar RE invariably provokes portal
hypertension. Further studies are required to better elucidate the
mechanism underlying this phenomenon and to investigate the
role of RE as an alternative to PVE in the management of patients
with potentially resectable liver tumours.
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